Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Responses to first-line systemic therapies in patients with hepatocellular carcinoma with TERT promoter mutations.
Authors
Jeremy Chang
UC San Diego, La Jolla, CA;
Jeremy Chang , Kathryn J Fowler , Pablo Tamayo , Adam Burgoyne
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 589)
DOI
10.1200/JCO.2023.41.4_suppl.589
Abstract #
589
Poster Bd #
F1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Outcomes of patients with hepatocellular carcinoma (HCC) treated in the lenvatinib (LEN) and immunotherapy era (2018-2021) compared to the sorafenib (SOR) era (2008-2018).
First Author: Chloe Lim
Poster
2022 ASCO Annual Meeting
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.
First Author: Julien Edeline
Poster
2022 ASCO Annual Meeting
Comparative efficacy of novel combination immunotherapy strategies for unresectable hepatocellular carcinoma (HCC): A network metanalysis of landmark phase III trials.
First Author: Claudia A.M. Fulgenzi
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.
First Author: Julien Edeline